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Behavioral findings suggest that the effects of neostriatal glutamate and ascorbate are opposed to those of neostriatal dopamine.
Recent evidence also indicates that glutamate and ascorbate are linked via a carrier-mediated heteroexchange process, suggesting that ascorbate may act through the glutamate system to influence behavior. In order to assess glutamate-ascorbate interactions and their influence on the behavioral output of the basal ganglia, glutamate and homocysteic acid (a glutamate reuptake blocker) as well as NMDA antagonists were infused into the neostriatum of freely moving rats while extracellular neostriatal ascorbate was monitored via electrochemically modified carbon-fiber electrodes. Neostriatal 3,4-dihydroxyphenylacetic acid (DO-PAC), a major dopamine metabolite, also was recorded in order to assess the dependency of any drug effect on the nigrostriatal dopamine system. lntraneostriatal infusions of L-glutamate (1 pg/pl), but not L-homocysteic acid (30 rglpl), elevated extracellular neostriatal ascorbate levels. Neither of these drugs had any effect on neostriatal DOPAC or overt behavioral activity. lntraneostriatal infusion of the noncompetitive NMDA antagonist dirocilpine (MK-801; 3 pg/pl) or the competitive NMDA antagonist 3-(2-carboxypiperazin-4-yl)-propyl-1 -phosphonene (CPPene; 5 rg/Al) decreased neostriatal ascorbate but had no effect on neostriatal DO-PAC. Both dizocilpine and CPPene activated behavior in intact and sham-lesioned animals as well as in animals with near-total depletions of neostriatal dopamine following a 6-hydroxydopamine lesion. When administered systemically, however, dizocilpine (1 .O mg/kg) significantly increased neostriatal DOPAC. This effect appears to be regulated via midbrain NMDA receptors, in that this effect was completely abolished by electrolytic lesions of the substantia nigra pars reticulata. In addition, systemic dizocilpine substantially lowered the level of extracellular ascorbate (in both intact/sham and substantia nigra-lesioned animals), but subsequent intraneostriatal infusions of glutamate increased ascorbate levels to the'same extent as that observed in undrugged animals.
Taken together, these results suggest that neostriatal NMDA receptors regulate basal, but not glutamate-stimulat-ed, increases in neostriatal ascorbate and also induce behavioral hyperactivity through nondopaminergic mechanisms. Conversely, NMDA antagonist-induced increases in nigrostriatal dopamine synthesis, as reflected through changes in neostriatal DOPAC, appear to be regulated by NMDA receptors located in the substantia nigra. These results provide support for a functional link between neostriatal glutamate and ascorbate and suggest that neostriatal glutamate release inhibits the behavioral output of the basal ganglia.
[Key words: ascorbate, glutamate, NMDA, dizocilpine, CPPene (3-(2-carboxypiperazin-I-yl)-propyl-1 -phosphonene), DOPAC, homocysteic acid, in vivo woltammetry, neostriatum] Converging evidence suggests multiple interactions between ascorbate and glutamate in the neostriatum. At the presynaptic level, ascorbate appears to be colocalized with glutamate in corticoneostriatal neurons, and the release of these substances is mediated by a complex heteroexchange process at the axon terminal. Thus, lesions of this pathway markedly deplete both neostriatal ascorbate (Basse-Tomusk and ) and glutamate (Walaas, 198 1; Hassler et al., 1982; Young and Bradford, 1986) whereas glutamate infusions into the neostriatum increase neostriatal ascorbate release and this process is blocked by glutamate reuptake blockers (O'Neill et al., 1984; Cammack et al., 1991; Ghasemzadeh et al., 1991) . Moreover, because glutamate receptor antagonists have been reported to have no effect on glutamate-induced increases in neostriatal ascorbate (Cammack et al., 199 l) , glutamate-induced neostriatal ascorbate release appears to be regulated via glutamate reuptake sites rather than presynaptic glutamate receptors. Postsynaptically, ascorbate and glutamate appear to interact in their influence on neostriatal neuronal activity. Iontophoretic application ofascorbate and glutamate, for example, activates a much larger proportion of neostriatal neurons than iontophoresis of ascorbate alone (Gardiner et al., 1985) . It seems likely, therefore, that endogenous glutamate regulates increases in neostriatal ascorbate release, while ascorbate appears to modulate neostriatal neuronal activity, especially in the presence of glutamate.
Ascorbate and glutamate also have been shown to regulate behavior. Thus, both systemic (Tolbert et al., 1979; and intraneostriatal (White et al., 1990 ) administration of ascorbate attenuates the behavioral response to the indirect dopamine agonist amphetamine while ascorbate potentiates the catalepsy produced by the dopamine antagonist haloperidol Dorris and Dill, 1986) . Fur-thermore, repeated coadministrations of ascorbate and haloperidol potentiate the supersensitive behavioral response to the direct dopamine agonist apomorphine typically observed following treatment with haloperidol alone (Pierce et al., 1991) . Although the mechanisms underlying these behavioral changes remain to be determined, it seems clear that ascorbate modulates dopamine-induced behavioral activation.
The recent development of selective glutamate antagonists has greatly aided the assessment of the effects of central glutamate systems on behavior. Thus, systemic administration of the noncompetitive NMDA antagonist dizocilpine (MK-801) induces locomotion and sniffing as well as motor ataxia (Koek et al., 1988; Ford et al., 1989; Lehmann-Masten and Geyer, 199 1; Kretschmer et al., 1992) . Because high doses of glutamate antagonists are known to increase neostriatal dopamine (Barbeito et al., 1990; Imperato et al., 1990; Leviel et al., 1990; Moghaddam and Gruen, 199 1; Keefe et al., 1992) it was suggested that NMDA antagonists stimulate behavior through interactions with the dopamine system (Hiramatsu et al., 1989; Loscher and Honack, 1992) . However, the doses of NMDA antagonists required to stimulate dopamine release may not reflect a primary action at the NMDA receptor (Moghaddam and Gruen, 199 1; Keefe et al., 1992) , and dizocilpine has been shown to stimulate motor responses in monoamine-depleted mice Carlsson et al., 199 1; Svensson et al., 199 1) . Furthermore, injection of the NMDA antagonist D,L-2-amino-5-phosphonovaleric acid (AP-5) directly into the nucleus accumbens of monoamine-depleted mice is known to induce locomotor activation (Svensson and Carlsson, 1992) . Collectively, these findings suggest that striatal glutamate exerts an inhibitory influence on locomotion via nondopaminergic mechanisms .
Based on these lines of evidence, it appears that neostriatal ascorbate may act via glutamatergic mechanisms to influence behavioral activity. To test this hypothesis, we combined intraneostriatal infusions with voltammetric techniques to assess glutamate's control of neostriatal ascorbate release. We also assessed changes in extracellular 3,4-dihydroxyphenylacetic acid (DOPAC), a major dopamine metabolite, as an indirect measure of dopaminergic activity. All recordings were obtained from freely moving animals in order to relate ongoing changes in neostriatal ascorbate and DOPAC with behavioral activity. Our results indicate that NMDA antagonists regulate basal neostriatal ascorbate and also stimulate behavior through nondopaminergic mechanisms. Conversely, NMDA antagonist-induced increases in dopamine synthesis and release appear to be regulated by NMDA receptors located in the substantia nigra.
Materials and Methods
Animals. Adult, male, Sprague-Dawley rats (300-400 gm), bred in our animal colony, were used as subjects. They were housed individually under standard laboratory conditions with food and water available continuously. All animal use protocols followed guidelines established by the National Institutes of Health and were approved by the Indiana University Institutional Animal Care and Use Committee.
Surgery. Prior to surgery, all animals were anesthetized with Equithesin(Oi33 ml/kg, i.p.); 6-hydroxydopamine (6-OHDA) rats were pretreated with the monoamine oxidase inhibitor pargyline (40 mg/kg, i.p.) and the norepinephrine reuptake blocker desipramine (25 mg/kg, i.p.). All animals then were placed in a stereotaxic instrument, and a hole was drilled unilaterally through the skull over the neostriatum (1 .O mm anterior and 2.5 mm lateral to bregma; Paxinos and Watson, 1982) . For 6-OHDA lesions, a second hole was drilled over the medial forebrain bundle (4.0 mm posterior and 2.0 mm lateral to bregma), a cannula was lowered through this hole into the medial forebrain bundle (8 mm ventral to the dura), and 2.0 rl(4.0 rg/rl) of 6-OHDA was infused over a 5 min period. After the infusion, the cannula remained in place for 5 min. For unilateral substantia nigra pars reticulata (SNR) lesions, an insulated tungsten electrode was lowered to the following coordinates relative to bregma: 2.5 mm lateral, 5.5 mm posterior, and 8.0 mm ventral. A 300 PA DC current was administered for 2 min between the electrode tip (cathode) and an alligator clip (anode) attached to the fascia at the edge of the incision. After lesioning, the cannula or lesioning electrode then was removed and a plastic cylindrical hub, designed to mate with an electrode holder for voltammetric recordings (see Pierce et al., 1992b , was centered over the hole above the neostriatum and cemented onto the skull. Control rats received the same treatment as lesion animals, including lowering the cannula or electrode into the brain, but no neurotoxin or current was administered. Following surgery, all animals were treated with 0.20 ml (25 mg) of Rocephin (Roche) to minimize infection. Voltammetric recordings were performed after a recovery period of approximately 7 d.
Voltammetry.
Microvoltammetric
electrodes were prepared from Thomell P-55 carbon fibers (Union Carbide) as described previously (Ewing et al., 1982; Kamata et al., 1986) . The active electrode surface is 200 pm in length with a 5 pm radius. Each electrode was treated in a citrate-phosphate buffer solution by application of a triangular wave (70 Hz, 0.09-3.0 V vs a saturated calomel reference electrode) for 20 set followed by 10 set of 0.5 V cathodal current, 3 set of 0.9 V anodal current, and 8 set of 1.5 V cathodal current. This treatment modifies the active surface of the electrode to allow discrimination of ascorbate from catechols and other easily oxidizable compounds (Gonon et al., 1980, 198 1) . Each electrode was then tested with staircase voltammetry in a solution containing 100 PM ascorbate and 20 PM DOPAC until the response stabilized.
For in vivo voltammetry, the electrode was secured in a holder equipped with a stainless steel, luer-lock fitting that mates with the hub placed on the animal's skull during surgery. The holder includes a threaded assembly that allows the electrode to be raised and lowered through the brain (Pierce et al., 1992b; Rebec et al., 1993) . The holder also contains a 33-gauge infusion cannula, which allows drugs to be administered close (100-500 pm) to the active surface of the voltammetric electrode. The electrode and infusion cannula were lowered 5 mm ventral to the brain surface into the neostriatum. Generation of waveforms for staircase voltammetry and storage of sampled current was performed by a computer (IBM-XT) interfaced to a locally constructed potentiostat of conventional three-electrode design (Ewing et al.. 1982) . The carbonfiber served as the working electrode; while the stainless steel infusion cannula served as both the reference and auxiliary electrodes. A potential was applied to the working electrode in 6 mV steps from -100 to +500 mV versus reference to ensure oxidation of ascorbate and DOPAC.
Short pulses (98 msec) were used to restrict sampling to the solution pool near the electrode surface. The scan rate was set at 20 mV/sec; scans were obtained at 1 min intervals. Voltammograms display peaks representing ascorbate (approximately 150 mV vs reference) and DO-PAC (approximately 300 mV vs reference), as well as a third more positive peak thought to represent 5-hydroxyindoleacetic acid and uric acid (Cespuglio et al., 198 1; Crespi et al., 1984) .
Drug-induced changes in extracellular ascorbate were tested after a stable baseline was established for voltammetry and all animals were resting quietly. Separate groups of animals received infusions of L-glutamate (1 &PI), L-homocysteic acid (10 pg'pl), dizocilpine (3 p$r.~l), 3-(2-carboxvuinerazin-4-vl)-orouvl-1 -ohosuhonene (CPPene: 10 ua'ul).
or 0.9% saline. Dizocilpine and CPPene at these same doses also were infused into the neostriatum of unilaterally 6-OHDA-lesioned animals.
The flow rate for all infusions was 10 pl/hr. In all instances, the infusion lasted for the duration of the voltammetric recording period. The doses of these drugs when administered intraneostriatally are known to produce either reliable increases in neostriatal ascorbate or characteristic patterns of locomotion and stereotyped behavior (R. C. Pierce and G. V. Rebec, unpublished observations) . In all cases, voltammetric recordings continued for another 50 min. Dizocilpine also was systemically administered to intact, sham, and SNR-lesioned animals at a dose (1 mg/kg) known to increase behavioral activation and neostriatal DO-PAC while decreasing neostriatal ascorbate (Pierce and Rebec, 1992) . Fifty minutes following the systemic administration of dizocilpine to intact/sham animals, glutamate (1 &PI) was infused into the neostriatum and voltammetric signals were recorded for another 10 min.
When voltammetric recording was completed, all animals were anesthetized with sodium pentobarbital. Some of the working electrodes used for each drug group were removed for postcalibration in a solution containing 100 PM ascorbate and 20 WM DOPAC. In order to verify the recording site, current was passed through the electrodes that remained in the brain to produce a small lesion. Following transcardial perfusion with normal saline and 10% formalin, brains were removed from the lesioned animals. Brain tissue was subsequently frozen, sectioned, and stained with cresyl violet for histological analysis.
Behavior. Individual items of each drug-specific behavioral response were recorded for 1 min intervals every 10 min beginning immediately following systemic drug administration or onset of the intraneostriatal drug infusion. Locomotion, sniffing, rearing, repetitive head movements, and vacuous chewing were rated according to their intensity (0 = not present, 1 = mild, 2 = moderate, 3 = extreme) and duration (1 = discontinuous, 2 = continuous) during each observation period. These ratings were multiplied to yield a single value (e.g., the maximum score at each observation interval is 3 x 2), as previously described . The behavioral score for each individual item of behavior reflects the average score across each of the 10 min observation periods.
Drugs. D-Amphetamine sulfate (Sigma), L-glutamate (Sigma), L-homocysteic acid (Sigma), CPPene (Sandoz), and dizocilpine (RBI) were mixed in 0.9% saline. Amphetamine was mixed as the free base; all other drugs were expressed as the salt.
Statistics. Voltammograms were expressed as the percentage baseline response at each 10 min interval following drug treatment. Mixedfactors analyses of variance were performed on all data. The drug treatments and the 10 min intervals served as the between-and withinsubjects factors, respectively. Further pairwise comparisons were assessed with Fisher's least significant difference (LSD).
Results
All lesions marking our voltammetric recording sites were located in the anterior neostriatum, approximately 2.5 mm lateral to the midline and 4.0-5.0 mm ventral to the brain surface. Similar to previous findings (Ewing et al., 1982; Pierce et al., 1992a) , basal extracellular ascorbate levels, based on postcalibration values, did not differ between the intact/sham (238 f 20 PM, II = 13) and 6-OHDA (265 f 44 KM, y2 = 6) groups. These values are comparable with those reported in previous studies (Gonon et al., 1980; Schenk et al., 1982; Wightman et al., 1987; Basse-Tomusk and Rebec, 1991) . Based on postcalibration data, the level of basal neostriatal DOPAC recorded from intact/sham animals (20.7 rfI 1.9 KM, n = 13) was similar to that reported elsewhere (Schenk et al., 1982; Basse-Tomusk and Rebec, 1991; Pierce and Rebec, 1992) . Conversely, there was no detectable DOPAC peak following 6-OHDA treatment, suggesting a greater than 95% destruction of dopaminergic afferents in these animals (Zigmond et al., 1990; Hollerman et al., 1992) . Basal neostriatal ascorbate and DOPAC did not differ significantly between the intact and sham groups; therefore, these groups were combined for comparison to 6-OHDA-lesioned animals.
Effects of intraneostriatal saline and glutamate agonists on neostriatal ascorbate and DOPAC As depicted in Figure 1 tively. The responses of intact and sham-lesioned animals following saline (as well as all drug administrations) were not significantly different. Therefore, these groups were combined for comparison to the 6-OHDA group in all of the following experiments. As expected, intraneostriatal infusions of glutamate (1 &pl) produced a sharp, yet transient, increase in the extracellular level of neostriatal ascorbate (p < 0.0001). Conversely, infusion of the nonselective reuptake blocker homocysteic acid (10 &pl) did not significantly alter extracellular ascorbate in the neostriatum. Neither glutamate nor homocysteic acid infusions, however, produced significant changes in DOPAC. The results of these infusion experiments are summarized in Figure 2 . Because glutamate and homocysteic acid are potentially neurotoxic, histologies were closely examined. In no case, however, was there evidence of gliosis other than that typically observed along the electrode tract. was administered 50 min previously on neostriatal ascorbate. Responses are as presented in Figure 1 . Note the decrease in neostriatal ascorbate over the 50 min period following the systemic administration of dizocilpine. Note also the increase in neostriatal ascorbate in these same animals following the intraneostriatal administration ofglutamate. This glutamate-induced ascorbate release is similar in magnitude and time course to that observed in undrugged animals (see Fig. 2 , top).
Eflects of intraneostriatal NMDA antagonists on neostriatal ascorbate and DOPAC As shown in Figure 3 , intraneostriatal administration of CPPene (10 pg/pl) or dizocilpine (3 pg/~l) significantly decreased ascorbate but had no effect on DOPAC in the neostriatum of both the intact/sham and 6-OHDA groups during the 50 min recording period (p < 0.0001). It is unlikely that the observed effects on ascorbate or behavior (see below) were due to diffusion of the drug up the infusion cannula since dizocilpine (3 Ilg/pl) infusions into cortex (3 mm ventral to dura) just dorsal to the neostriatal recording site produced no effect on either neostriatal ascorbate or behavior (n = 2; data not shown).
Effects of intraneostriatal glutamate infusion following systemic dizocilpine
In order to assess the effects ofNMDA antagonism on the ability of glutamate to increase neostriatal ascorbate, glutamate (1 pg/ ~1) was infused into the neostriatum 50 min after systemic administration of dizocilpine (1 mg/kg). As shown in Figure 4 , subcutaneous dizocilpine significantly decreased neostriatal ascorbate (p < 0.0001). The subsequent infusion of glutamate into the neostriatum resulted in a frank, short-lived increase in neostriatal ascorbate similar to that produced by glutamate infusions into the neostriatum of undrugged animals.
Effects of systemically administered dizocilpine on neostriatal ascorbate and DOPAC in intact/sham and SNR-lesioned animals Consistent with previous reports (Weihmuller et al., 199 1; Pierce and Rebec, 1992) , systemically administered dizocilpine significantly decreased neostriatal ascorbate while increasing extracellular concentrations of neostriatal DOPAC (p < 0.0001).
As shown in Figure 5 , whereas unilateral lesions of the SNR Eflects of glutamate agonist and antagonist administration on individual items of behavior
As shown in Table 1 , intraneostriatal saline produced no behavioral activation. These results parallel previous reports that rats habituated to the behavioral arena show no behavioral response to systemic saline injections (Pierce and Rebec, 1990; Pierce et al., 1992a) . Intraneostriatal administration of glutamate or homocysteic acid also failed to elicit behavioral activity (data not shown). Conversely, Table 1 indicates consistent behavioral activation during intraneostriatal infusion of dizocilpine or CPPene. Elevated sniffing (p < 0.001) and repetitive head movements (p < 0.0001) were most prominent, though increased locomotion (p < 0.0001) and chewing (p < 0.001) also were observed in both intact/sham and 6-OHDA-lesioned animals. Behavioral increases were evident in each case at lO-20 min following infusion onset, and they persisted for the entire observation period (50 min). These behavioral effects were similar to those observed following the systemic administration of dizocilpine (Table 1) .
Discussion
Our results demonstrate that (1) neostriatal ascorbate release is linked to the glutamate reuptake site and is influenced by neostriatal NMDA receptors, (2) neostriatal NMDA receptors both decreases neostriatal ascorbate and increases behavioral activation, and (3) NMDA antagonist-induced reductions in ascorbate release and increases in behavioral activity are not dependent on forebrain dopamine release. However, systemic administration of an NMDA antagonist reliably increases neostriatal DOPAC. This effect appears to be mediated by midbrain NMDA receptors since SNR lesions completely abolished this effect. Taken together, these results suggest that neostriatal ascorbate may act via glutamatergic mechanisms to influence neostriatal function and, furthermore, that the net effect of neostriatal glutamate release is the inhibition of basal ganglia motor output.
Ascorbate-glutamate heteroexchange: influence of NMDA receptors
Our results confirm previous reports (O 'Neill et al., 1984; Cammack et al., 1991; Ghasemzedah et al., 199 1) that infusions of glutamate into the neostriatum elevate neostriatal ascorbate release. The link between ascorbate and glutamate has been suggested to occur via an active heteroexchange process at the glutamate reuptake site. This position is supported by evidence that hippocampal glutamate-induced ascorbate release is not only dose dependent but also completely inhibited by the coadministration of the glutamate reuptake blockers homocysteic acid and D,L-threo-@-hydroxy-aspartic acid (Cammack et al., 1991) . In addition, coadministration of the nonselective glutamate antagonist kynurenic acid has no effect on glutamateinduced increases in hippocampal ascorbate (Cammack et al., 199 1) . Thus, glutamate-induced increases in extracellular ascorbate release appear to be mediated by the glutamate reuptake site, and this effect is independent from the influence of glutamate receptors. Recent evidence, however, suggests that the NMDA glutamate receptor may play a role in the regulation of neostriatal ascorbate release. We have shown, for example, that systemic administration of dizocilpine significantly decreases neostriatal ascorbate and attenuates amphetamine-induced ascorbate release (Pierce and Rebec, 1992) . Furthermore, our present results show that intraneostriatal administration of either competitive (CPPene) or noncompetitive (dizocilpine) NMDA antagonists sharply reduce extracellular neostriatal ascorbate levels. Reconciling these data with the heteroexchange hypothesis of ascorbate release requires an understanding of the somewhat unique effects of stimulating terminal glutamate receptors. Thus, unlike striatal dopamine terminal receptors, which attenuate dopamine synthesis and release (Chesselet, 1984; Drukarch and Stoof, 1990) , terminal NMDA and non-NMDA glutamate receptors actually facilitate glutamate release (Ferkany et al., 1982; Collins et al., 1983; Ferkany and Coyle, 1983) , while increasing glutamate terminal excitability (Garcia-Munoz et al., 199 1, 1992) . This presynaptic positive feedback mechanism has been suggested to contribute to glutamate-induced neurotoxicity as well as the induction of long-term potentiation (Biziere and Coyle, 1978; Garcia-Munoz et al., 1992) . Thus, blockade of this presynaptic positive feedback via NMDA antagonists should result in decreased glutamate release. If neostriatal ascorbate and glutamate release are coupled via a carrier-mediated heteroexchange process, then it is not surprising that NMDA antagonists, which would decrease glutamate release, also would decrease ascorbate release as demonstrated in our present experiments. It also is possible, however, that antagonism ofNMDA receptors located postsynaptically on striatal output neurons could inhibit the activity of the corticoneostriatal pathway, and thus the release of both neostriatal glutamate and ascorbate, via feedback through a striato-nigro-thalamo-cortico-striatal feedback loop (see Basse-Tomusk and Rebec, 1990; Pierce et al., 1992a) . It is unlikely that this "long-loop" plays a primary role in NMDA antagonist-induced decreases in neostriatal ascorbate since in the present experiments substantia nigra lesions did not significantly inhibit the ability of dizocilpine to decrease neostriatal ascorbate.
In order to assess the relationship between glutamate receptors and glutamate-induced neostriatal ascorbate release, we infused glutamate into the neostriatum of animals pretreated with a systemic injection of dizocilpine. Consistent with previous results (Pierce and Rebec, 1992) , systemic dizocilpine significantly decreased basal neostriatal ascorbate 50 min after its administration. The subsequent infusion of glutamate into the neostriatum, however, resulted in a sharp increase in neostriatal ascorbate similar to the glutamate response observed in undrugged animals. Thus, while NMDA receptors may regulate basal ascorbate levels, NMDA receptor antagonism does not influence the ability of glutamate to increase extracellular ascorbate levels.
Ascorbate-glutamate interactions: influence on behavior Besides decreasing neostriatal ascorbate, systemic administration of dizocilpine also has been shown to produce a characteristic behavioral syndrome characterized by stereotypy, hyperlocomotion, and ataxia (Koek et al., 1988; Carlsson and Svensson, 1990; Loscher and Honack, 1992; Pierce and Rebec, 1992) . Hyperactivity also has been observed following the in-fusion ofNMDA antagonists into the neostriatal complex. Thus, intraneostriatal administration of AP-5 induced sniffing stereotypy (Schmidt, 1986) , while intra-accumbens infusions of this NMDA antagonist produced pronounced locomotor stimulation (Svensson and Carlsson, 1992) . Our results confirm and extend these findings. We found, for example, that intraneostriatal administration of dizocilpine or CPPene produces a marked increase in a variety of behaviors, most notably locomotion, sniffing, head bobbing, and chewing. Our results also support suggestions that NMDA antagonists stimulate behavior independently from an action on the dopamine system Carlsson et al., 199 1; Svensson et al., 199 1) . That is, intraneostriatal dizocilpine and CPPene stimulated behavior without producing an effect on neostriatal DOPAC. Furthermore, intraneostriatal NMDA antagonist administration caused behavioral activation in animals with near-total depletions of striatal dopamine following 6-OHDA administration into the medial forebrain bundle. In fact, there was a slight increase in overall behavioral activation in 6-OHDA-lesioned animals relative to controls, particularly in the CPPene groups. Taken together, these results suggest that NMDA antagonistinduced hyperactivity is mediated in the neostriatum through a nondopaminergic mechanism.
It is likely that the NMDA antagonist-induced depletion of neostriatal ascorbate also contributed to the behavioral effects of these drugs. Ascorbate, for instance, could interact with the corticoneostriatal glutamate system to influence behavior. Thus, increases in neostriatal ascorbate should reverse the action of the glutamate reuptake site if, as recent evidence suggests, glutamate and ascorbate are linked via a heteroexchange process (see above). Ascorbate depletions following NMDA antagonist administration, therefore, should inhibit glutamate release, resulting in increased behavioral hyperactivity through disinhibition. Ascorbate also appears to have a more direct influence on neostriatal transmitter systems. Thus, ascorbate has been shown to inhibit NMDA receptor function (Majewska et al., 1990 ) and the binding of dopamine agonists and antagonists to D, and D, dopamine receptors (Hadjiconstantinou and Neff, 1983; Tolbert et al., 1992) . Based on these lines of evidence, it is not surprising that fluctuations in neostriatal ascorbate influence behavior. In fact, increases in extracellular neostriatal ascorbate are known to attenuate the behavioral response to amphetamine and to potentiate the catalepsy produced by haloperidol White et al., 1990) . Collectively, these results suggest that increased neostriatal ascorbate concentrations inhibit behavioral activation either presynaptically through interactions with the corticoneostriatal glutamate system or postsynaptically through some as yet undetermined interaction with glutamate and/or dopamine receptors.
Glutamatergic control of nigrostriatal dopamine synthesis and release It has been shown that systemic administration of dizocilpine significantly increases extracellular levels of neostriatal DOPAC and dopamine (Rao et al., 1990; Weihmuller et al., 199 1; Miller et al., 1992; Pierce and Rebec, 1992) , although the effects of dizocilpine on DOPAC, which mainly reflects alterations in dopamine synthesis (Zetterstrom et al., 1988) , are much more pronounced than on dopamine itself (Weihmuller et al., 199 1) . Our present findings demonstrate that dizocilpine-induced increases in neostriatal DOPAC are not mediated exclusively by mechanisms intrinsic to the neostriatum. Thus, intraneostriatal administration of dizocilpine at a dose that produced alterations in behavior did not affect extracellular neostriatal DOPAC levels. Electrolytic lesions of the SNR, however, completely abolished the ability of systemically administered dizocilpine to increase neostriatal DOPAC. It is conceivable, therefore, that dizocilpine-induced increases in dopamine synthesis, as measured by neostriatal DOPAC formation, are regulated by NMDA receptors in the SNR. This hypothesis is consistent with preliminary data that intranigral, but not intraneostriatal, infusions of dizocilpine increase neostriatal dopamine release (Miller et al., 1992) .
Alternatively, the SNR may regulate dopaminergic activity as part of a complex feedback system that receives inputs from a large number of forebrain regions rich in NMDA receptors. According to this model, dopaminergic activity may change only when a sufficient number of these receptors are blocked. Indeed, systemic, but not iontophoretic, administration of dizocilpine elevates the overall firing rate of midbrain dopaminergic neurons, and this effect is blocked by a hemitransection of descending forebrain efferents, many of which project to SNR (Zhang et al., 1992) . Thus, SNR lesions would be expected to abolish the increase in dopaminergic activity produced by systemic dizocilpine, and to the extent that neostriatal DOPAC parallels dopamine, our results support this view. Moreover, rather than acting as the sole NMDA-rich forebrain region controlling dopaminergic activity via descending feedback loops, the neostriatum may share in this function with the nucleus accumbens, frontal cortex, and other relevant areas. Thus, although a failure of intraneostriatal infusions of dizocilpine to elevate DOPAC argues against an exclusive role for neostriatal NMDA receptors in the control of dopaminergic activity, our results do not rule out the participation ofother forebrain regions. It appears, therefore, that the mechanisms by which glutamate receptors regulate the activity of ascending dopaminergic neurons are complex and require further research on both the processes within the substantia nigra as well as forebrain areas outside the neostriatum.
Conclusions
Our results demonstrate a functional relationship between neostriatal ascorbate and glutamate independent from the influence of neostriatal dopamine. That is, neostriatal ascorbate appears to act, either primarily or in part, via glutamatergic mechanisms to influence neostriatal function. Moreover, ascorbate influences neostriatal glutamate transmission presynaptically via an ascorbate-glutamate heteroexchange at the glutamate reuptake site and perhaps postsynaptically via NMDA receptor blockade (Majewska et al., 1990) . In view of recent reports of a glutamate deficiency in schizophrenia (Deutch et al., 1989; coupled with evidence that ascorbate may serve as an effective adjunct treatment (Kanofsky et al., 1989; Suboticanec et al., 1990) , further elucidation of the mechanisms underlying an ascorbate-glutamate interaction promises to shed light on what appears to be an important neurochemical component of complex behavioral activity.
